Track Akari Therapeutics, Plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Akari Therapeutics, Plc AKTX Open Akari Therapeutics, Plc in new tab

4.47 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 12, 2026

DCF Valuation

Tweak assumptions to recompute fair value for Akari Therapeutics, Plc (AKTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Akari Therapeutics, Plc Logo Akari Therapeutics, Plc Analysis (AKTX)

United Kingdom Health Care Official Website Stock

Is Akari Therapeutics, Plc a good investment? Akari Therapeutics, Plc (AKTX) is currently trading at 4.47 USD.

Earnings Schedule: Akari Therapeutics, Plc is expected to release its next earnings report on May 12, 2026.

Investor FAQ

Does Akari Therapeutics, Plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Akari Therapeutics, Plc?

Akari Therapeutics, Plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 12, 2026.

Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Exchange Ticker
NMS (United States) AKTX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Sept. 17, 2015 0.100000
Aug. 17, 2023 0.050000
March 31, 2026 0.030000
Jan. 3, 2014 0.200000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion